Pair page
Oxytocin with PT-141
Mechanism-tag overlap and published literature for Oxytocin and PT-141, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
neurohypophyseal-nonapeptide-hormone
melanocortin-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Oxytocin and PT-141 have published these mechanism-level observations. Not a co-administration recommendation.
PT-141 drives central desire/arousal via MC4R; oxytocin engages the affiliative/pair-bond circuit via OXTR. Some practitioners layer these for couples therapy or intimacy-focused protocols. Evidence is anecdotal; mechanistic complementarity is real.
Mechanistically aligned with PT-141's presumed oxytocinergic downstream signaling. Low-dose oxytocin (intranasal 10–40 IU) is used by some practitioners as an adjunct for the affiliative/emotional components of the PT-141 experience. Evidence is anecdotal.
Quick facts
Oxytocin
PT-141
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Oxytocin | Sikich L, Kolevzon A, King BH, McDougle CJ, Sanders KB, Kim SJ, Spanos M, Chandrasekhar T, Trelles MDP, Rockhill CM, Palumbo ML, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. N Engl J Med. 2021;385(16):1462-1473. PMID: 34614322. (SOARS-B —… PMID 34614322 | human study |
| 2015 | Oxytocin | Lawson EA, Marengi DA, DeSanti RL, Holmes TM, Schoenfeld DA, Tolley CJ. Oxytocin Reduces Caloric Intake in Men. Obesity. 2015;23(5):950-956. PMID: 25865294. PMID 25865294 | human study |
| 2013 | Oxytocin | Ott V, Finlayson G, Lehnert H, Heitmann B, Heinrichs M, Born J, Hallschmid M. Oxytocin reduces reward-driven food intake in humans. Obesity (Silver Spring). 2013;21(10):2086-2090. Diabetes. 2013;62(10):3418-3425. PMID: 23512597. PMID 23512597 | human study |
| 2011 | Oxytocin | Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci. 2011;15(7):301-309. PMID: 21696997. PMID 21696997 | human study |
| 2007 | Oxytocin | Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves "mind-reading" in humans. Biol Psychiatry. 2007;61(6):731-733. PMID: 17137561. PMID 17137561 | human study |
| 2005 | Oxytocin | Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci. 2005;25(49):11489-11493. PMID: 16339942. PMID 16339942 | human study |
| 2005 | Oxytocin | Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435(7042):673-676. PMID: 15931222. PMID 15931222 | human study |
| — | Oxytocin | du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc. 1953;75(19):4879-4880. (Original total chemical synthesis of oxytocin; basis of 1955 Nobel Prize in Chemistry.) | mechanism / discovery |
| 2026 | Oxytocin | US Food and Drug Administration. Pitocin (oxytocin injection) prescribing information. FDA Approved Product Label. Accessed April 2026. | regulatory / registry |
| 2021 | Oxytocin | Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Mol Psychiatry. 2021;26(1):80-91. PMID: 32433515. PMID 32433515 | research article |
| 2020 | Oxytocin | Lawson EA, Olszewski PK, Weller A, Blevins JE. The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis. J Neuroendocrinol. 2020;32(4):e12805. PMID: 31901090. PMID 31901090 | research article |
| 2019 | Oxytocin | Salati JA, Leathersich SJ, Williams MJ, Cuthbert A, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev. 2019;4:CD001808. PMID: 31016714. PMID 31016714 | research article |
| 2022 | PT-141 | Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Sex Med. 2022. PMID: 35230162. PMID 35230162 | human trial, Phase 3 |
| 2019 | PT-141 | Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. DOI: 10.1097/AOG.0000000000003500. PMID 31599840 | human trial, Phase 3 |
| 2021 | PT-141 | Kingsberg SA, Clayton AH, Portman D, et al. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. J Womens Health (Larchmt). 2021. PMID: 33538638. PMID 33538638 | human trial |
| 2016 | PT-141 | Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: A randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3… | human trial |
| 2008 | PT-141 | Rosen RC, Diamond LE, Earle DC, Shadiack AM. Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study. J Urol. 2008;179(3):1060-1066. | human trial |
| — | PT-141 | ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (RECONNECT 301). NCT02338960. | human trial |
| 2004 | PT-141 | Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra… PMID 14999221 | human study |
| 2003 | PT-141 | Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PMID: 12851303. PMID 12851303 | human study |
| 2004 | PT-141 | Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201-10204. PMID: 15226502. PMID 15226502 | preclinical, in vivo |
| 2019 | PT-141 | US Food and Drug Administration. VYLEESI (bremelanotide injection) prescribing information. 2019. Reference ID: 4436693. | regulatory / registry |
| 2022 | PT-141 | Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182. PMID: 35147466. PMID 35147466 | research article |
| 2019 | PT-141 | Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606. PMID: 31429064. DOI: 10.1007/s40265-019-01187-w. PMID 31429064 | research article |
Related pair pages
More research context
Frequently asked
Have Oxytocin and PT-141 been studied together?
Researchers have published mechanistic-level co-administration discussion of Oxytocin and PT-141. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Oxytocin and PT-141 share?
Oxytocin and PT-141 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Oxytocin and PT-141?
Oxytocin: Approved (Pitocin, labor/PPH). PT-141: Approved 2019 (HSDD). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Oxytocin and PT-141?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Oxytocin profile and the PT-141 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026